Cybersecurity for hospitals and health systems

Understand clinical cyber risk. Coordinate the response.

Bring device risks, segmentation assessments and remediation decisions into one hospital workspace. Review the evidence, assign ownership and track action with clinical context.

Assessment tools · Clinical risk workflows · Traceable evidence

Review evidence

Assess policy and review reported device risks

Coordinate action

Connect owners, remediation plans and clinical dependencies

Preserve decisions

Track revisions, reviews and supporting evidence

Explore the Guardra platform

Explore assessment, investigation and evidence workflows in a guided demo using fictional healthcare data. Workspace access and assessment engagements are arranged directly with Guardra, with scope, data handling and acceptance criteria agreed before onboarding.

Seven areas of review. Evidence and limits together.

Everything here is derived from flow metadata and firewall configuration — addresses, ports, direction, volume, timing. No packet capture, no payload, no protocol semantics. Each finding includes its evidence and coverage limits to support an informed review.

SEG-01

Segmentation that does not hold

“Your matrix says these zones do not communicate. Do they?”

Flows between zones your own matrix declares separated. In practice this is a rule left from a go-live nobody will touch, a management network that reaches everything because it had to during a migration, or a temporary path from an outage that was never reverted.

Evidence — The intent quoted from your matrix, against the specific flow records that contradict it.

Cannot establish — Observing flows proves a path is open. Observing none proves nothing — the path may be unused, or the collection point may not sit where you think it does.

Maps to

  • HIPAA Security Rule NPRM — proposed segmentation specification
  • HPH CPG — Network Segmentation (enhanced)
SEG-02

Device networks reachable from general IT

“Can a general-purpose subnet reach the biomedical device range?”

Flows between corporate address space and the ranges clinical engineering identifies as biomed. The interesting direction is usually inbound — a workstation that can reach the drug-library server, or a corporate subnet with a path to a modality.

Evidence — Source and destination address ranges, ports, direction and volume across the boundary you define.

Cannot establish — Flow records identify addresses, not devices. We cannot tell you a given host is an infusion pump — only that something in the range you nominated is reachable from somewhere it should not be.

Maps to

  • HIPAA Security Rule NPRM — proposed segmentation specification
INV-01

Addresses absent from your inventory

“What is talking on this network that is not on your list?”

Active addresses in the flow records that are absent from your CMDB or biomed inventory. Routinely: modality workstations, a vendor jump host, research equipment a department bought on a grant, and whatever facilities connected last quarter.

Evidence — Observed active addresses, diffed against the inventory you provide.

Cannot establish — This produces addresses and traffic patterns, not asset identification. Confirming what each one is remains your work — but knowing where to look is the expensive part.

Maps to

  • HIPAA Security Rule NPRM — proposed technology asset inventory
  • HPH CPG — Asset Inventory (enhanced)
EXP-01

Management planes reachable

“Which segments can reach the equipment that enforces your segmentation?”

Flows to management ports on firewalls, switches and infrastructure from segments that should not reach them. CISA has repeatedly flagged edge-device management exposure as an initial access route.

Evidence — Observed connections to management services, and the source segments they came from.

Cannot establish — Reachability observed in the collection window. A management path that saw no traffic in seven days is not shown to be closed.

Maps to

  • HIPAA Security Rule — access control
  • HPH CPG — Network Segmentation (enhanced)
RUL-01

Rules with no observed traffic

“How much of this policy is doing anything?”

Rules that matched nothing during the observation window, plus rules shadowed by broader rules above them. Shadowed rules are a static property of the configuration and can be stated with certainty; unused rules cannot.

Evidence — Rule-by-rule analysis of the configuration, against hits observed in the window.

Cannot establish — Seven days of no hits does not mean a rule is dead. Quarter-end, failover and annual processes all fall outside the window. These are candidates for review, never a delete list.

Maps to

  • HPH CPG — Network Segmentation (enhanced)
VND-01

Vendor paths into the device estate

“Which of your device vendors has a live route in right now?”

Standing remote access for imaging, lab and biomedical vendors — jump hosts, support tooling, and the site-to-site tunnel someone stood up for a go-live in 2021. Clinical engineering usually owns the relationship; the network team inherits the path.

Evidence — Flows to and from the vendor endpoints and maintenance windows you supply, and which internal segments they reach.

Cannot establish — This requires your vendor list — flow records show an external destination, not which support product it is. It shows a path carried traffic, never what was done over it, and a path dormant in the window is not a closed one.

Maps to

  • HIPAA Security Rule — access control
CFG-01

Configuration that contradicts itself

“Does the policy say what its author thought it said?”

Overlapping and redundant rules, objects permitting more than their name suggests, any-any rules surviving from a migration, and rules whose stated purpose no longer matches their effect.

Evidence — Static analysis of the configuration alone — no traffic required, so no window limitation applies.

Cannot establish — This says what the policy permits, not what has happened. A permissive rule with no traffic is still a permissive rule.

Maps to

  • HPH CPG — Network Segmentation (enhanced)
  • HIPAA Security Rule — access control

One boundary. Metadata only. A clearly defined outcome.

A focused assessment compares approved segmentation intent with configuration and traffic evidence for one boundary. Scope, handling terms and the accepting reviewer are agreed before customer data is transferred.

Evidence requirements

  • 1Configuration for one enforcement boundaryOne firewall or HA pair — not the estate. Panorama / FMC / FortiManager export or running-config.
  • 2Traffic records for the same boundaryFirewall logs, NetFlow / IPFIX or SIEM export. Metadata only — addresses, ports, direction, volume, timing.
  • 3Your intended segmentation matrixWhich zones may talk to which. A diagram, a spreadsheet, or a photo of the whiteboard.
  • 4Your asset inventory, if one existsOptional. Without it the inventory finding is skipped rather than guessed at.

A written, approved segmentation matrix is required to compare intent with evidence. Identify missing requirements during scoping so coverage gaps can be recorded before the assessment begins.

Assessment deliverables

Findings, each carrying the intent it contradicts quoted from your material, the evidence cited to specific records, and what it cannot establish. Plus a coverage statement: which paths the evidence does not cover, and why.

Written report, with delivery timing confirmed in the engagement terms.

No minimum finding count is promised. If no contradictions are found in the supplied evidence, the report records that result and its coverage limits.

What it is not

  • A scan, a probe, or a penetration test
  • Anything installed on your network
  • Anything touching a medical device
  • Packet capture, payload, or protocol-level analysis
  • A compliance certification, or evidence that stands alone in an audit
  • A hosted platform subscription; workspace access is agreed separately

Scope your assessment

Agree the boundary, evidence requirements, deliverables, fee and timeline before work begins. Start with a synthetic example to confirm the intended workflow and the question the assessment should answer.

Customer data requires counsel-reviewed handling terms and an applicable BAA, or a written no-PHI determination. Customer-controlled analysis environments are subject to the same scope and authorization review.

Start a conversation

Review network evidence with clinical context.

Clinical workflows depend on devices, shared services and vendor connections. Review these dependencies alongside the segmentation matrix and document the limits of the available evidence.

Where to look, and what a port does not prove

Port numbers can guide investigation but do not identify a protocol or device. Flow records contain no message payload. Confirm service identity with the system owner and application configuration.

PortProtocolWhy it matters
2575HL7 v2 / MLLP by conventionThe conventional port. A listener here is a strong hint, never a proof — you confirm what it is.
5000–6999Interface channels, typicallyNot a standard. Most estates allocate high ports per channel, so your real interface map is dozens of them and only you have the list.
104 · 11112DICOM by convention104 is the well-known port, 11112 the registered alternative. Which hosts use them is yours to confirm.
3389 · 5900 · 22Remote desktop / shellHow workstations get administered. Review whether the source segment is authorized for administration.
445 · 139SMBFile-based study transfer, downtime report drops, and the usual lateral movement path.
161 · 162SNMPDevice management traffic. We see that it happened and between which addresses — never its contents.
443 outbound to external hostsEgress, unattributedVendor support tooling usually looks like this. Flow records cannot tell you which product it is; the destination and your own vendor list can.

An interface engine may require connections across several clinical systems. Review its channel list and approved dependencies before interpreting cross-zone traffic as a segmentation issue.

Systems to include in scoping

Confirm whether these systems are in scope and represented in the matrix. Flow records alone cannot identify them; asset owners must resolve unexplained addresses and confirm expected connections.

  • Nurse call

    Frequently on its own VLAN, frequently reachable from more than it should be.

  • RTLS

    Badge and asset tracking. Talks to almost everything by design.

  • Pneumatic tube

    Confirm networked controllers, service dependencies and responsible owners.

  • Building management

    HVAC and chillers, often with a vendor tunnel older than the current network team.

  • Physical security

    Access control and camera VLANs, routinely trunked into clinical space.

  • Telemetry (WMTS)

    Patient monitoring with its own spectrum and its own gateway into the estate.

  • Digital signage & wayfinding

    Confirm ownership, network placement and any required external connections.

  • Infusion pump servers

    Include drug-library servers and their approved connections in the review.

Confirm ownership across clinical engineering, IT, facilities and vendors. Assessment results depend on the accuracy and coverage of the supplied zone, vendor and asset mappings.

Requirements, guidance, and proposed changes.

Review the stated status and primary source for each framework. Evidence mappings support assessment and do not establish compliance.

HIPAA Security Rule

HHS Office for Civil Rights

In force

Requires administrative, physical and technical safeguards over electronic protected health information, including access control, transmission security and audit controls. Network segmentation is not named in the current rule.

Findings evidence access-control posture. They do not by themselves demonstrate compliance, and nothing here should be presented to an auditor as if they did.

HIPAA Security Rule — proposed update

HHS OCR · NPRM published 6 Jan 2025

Proposed — not final

Would remove the addressable/required distinction and introduce network segmentation as an explicit implementation specification — a new requirement rather than the promotion of an existing addressable one. Also proposes a technology asset inventory and network map, multi-factor authentication on ePHI access subject to stated exceptions, and encryption at rest and in transit. Comment period closed 7 March 2025. As of September 2026 there is no final rule and no compliance deadline; it may change or be withdrawn.

The reason this work is worth doing now. An assessment surfaces contradictions between stated intent and observed traffic — useful preparation, not a compliance artefact.

HPH Cybersecurity Performance Goals

HHS

Voluntary

Voluntary goals split into essential and enhanced tiers. Network segmentation and asset inventory both sit in the enhanced tier. HHS has stated an intention to inform future enforceable standards with the CPGs.

Findings are mapped to the specific enhanced goal they inform.

The proposed Security Rule update is why this work is worth doing now. It has not been finalised, there is no deadline, and it may change or be withdrawn. An assessment surfaces contradictions between what your policy says and what your records show — that is useful preparation, and it is not a compliance artefact. Nobody should present it to an auditor as one.

Where isolation is the control doing the work.

Clinical equipment lifecycles, vendor dependencies and maintenance windows shape how security controls can be applied. Segmentation reviews need to account for those operational constraints.

Clinical continuity informs security decisions

Device maintenance, vendor support and service dependencies affect when a security change can be made. Review segmentation alongside clinical priorities, approved access and planned maintenance windows.

Evidence supports accountable review

Connect the intended policy with available observations and explicit coverage limits. Keep the source, responsible owner and review decision together so teams can assess the next action.

Coordination across operational teams

Security, clinical engineering, IT, facilities and vendors may share responsibility for a clinical service. Clear ownership and documented dependencies help them review proposed changes together.

Enforcement

Where intent is written down and where it stops being true.

Palo AltoCisco FMC / ASAFortinetCheck PointCore switching ACLsNAC posture

Records

What we read. Metadata only — addresses, ports, direction, volume, timing.

Firewall traffic logsNetFlow / IPFIXSIEM exportRule hit counters

Context you supply

Nothing here is inferred. Without it, findings degrade to unexplained addresses.

Zone-to-range mappingApproved vendor endpointsMaintenance windowsAsset inventory (optional)

Zones you define

You name the ranges — we do not infer them. Confirm that the matrix covers the required zones.

Clinical / EHRBiomedImaging / PACSLabPharmacyCorporateGuestVendor accessManagementResearch

There is a longer argument about clinical protocols being readable on the wire, which would let an assessment say what a flow is rather than merely that it exists. That needs packet capture, which needs a BAA and a clinical-engineering conversation. It is not what is being offered here, so it is not being claimed here.

Platform and assessment questions.

Guardra provides browser-based assessment tools and a hospital team workspace for device risks, security investigations, remediation planning, independent reviews and evidence exports. The interactive demo uses fictional healthcare data. Workspace access and assessment engagements are arranged directly with Guardra.

Start with a synthetic demonstration and a discussion of your requirements. For an assessment, agree the question, enforcement boundary, evidence requirements, accepting reviewer and commercial terms. Data handling must be approved before customer files are transferred.

Guardra works with supplied inventory and scoped source integrations to support review and coordinated action. It does not provide passive device discovery, device fingerprinting or autonomous endpoint containment. Integration scope and source coverage must be validated for each deployment.

Assessment tools compare supported policy inputs with declared assets and access requirements. Reviewers can inspect mismatches, unknown outcomes and modeled change effects. A scoped assessment can also review agreed configuration and flow evidence. Modeled results do not establish live connectivity or replace change approval.

The scoped assessment uses approved exports or an agreed customer-controlled analysis environment. It does not require active scanning or changes to clinical devices. Access, evidence transfer and any required organizational approvals are agreed before work begins. Optional platform connectors have their own permission and configuration requirements.

Use synthetic examples during qualification. Before any customer data is transferred, Guardra requires counsel-reviewed scope and handling terms, with an applicable executed BAA or a written determination that no PHI is in scope. Do not submit patient data, credentials, firewall configurations or traffic logs through the public contact form.

No. Guardra organizes evidence, recorded decisions and selected framework mappings. These support review but do not establish regulatory compliance. Consult the Trust Center for the availability of assurance documents and agree procurement requirements before onboarding.

Identify the gap during scoping. An assessment needs approved intent to compare with the evidence. Missing or ambiguous requirements are reported as coverage gaps; Guardra does not invent the intended policy.

The assessment findings belong to the customer. Findings are not published, reused or referenced without written permission. Confidentiality, authorized use, retention and deletion terms are agreed before evidence transfer. Hosted workspace and backup retention are described separately in the Privacy Policy.

Clinical equipment, vendor dependencies and maintenance constraints affect how security changes can be made. Guardra connects security evidence with clinical context so reviewers can assess the proposed action, responsible owner and implications for care continuity.

Define your security priorities. See how Guardra can support the review.

Explore the platform with synthetic data or discuss a scoped assessment. Agree the intended outcome, evidence requirements and handling terms before sharing customer data.

Start a conversation View assessment scope

Synthetic demo first · scope agreed before data transfer

Guardra support

How can we help?

From first steps to technical questions.

Guardra — Healthcare Cybersecurity and Evidence